Regulatory PathRegulatory requirements compared

Active substance

Misoprostol

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Cytotec200 µgTablet · Oral use28 BlisterSAR 40.35NCE · PrescriptionPfizer LimitedValid
Indications — CHI Daman Drug Formulary

DYSPEPSIA; MATERNAL AND CHILD HEALTHCARE- POSTPARTUM HEMORRHAGE, INDUCTION OF LABOR, MISCARRIAGE

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
CYTOTEC0.2MG; 0.1MGtablet · oralPFIZERPrescription27 Dec 1988
MISOPROSTOL0.1MG; 0.2MGtablet · oralANI PHARMSPrescription10 Jul 2002
MISOPROSTOL0.1MG; 0.2MGtablet · oralACQ PHARMAPrescription2 Jul 2019
MISOPROSTOL0.1MG; 0.2MGtablet · oralNOVEL LABS INCDiscontinued25 Jul 2012
MISOPROSTOL0.1MG; 0.2MGtablet · oralMICRO LABSDiscontinued17 Oct 2022

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
JAMP MISOPROSTOL02545284200 MCGTABLET · ORALJAMP PHARMA CORPORATION
MISOPROSTOL02244022100 MCGTABLET · ORALAA PHARMA INC
MISOPROSTOL02244023200 MCGTABLET · ORALAA PHARMA INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACMISOPROSTOL 100 MCG TABLET$0.4645per EA23 Sep 2026
US NADACMISOPROSTOL 200 MCG TABLET$0.71894per EA23 Sep 2026
NHS Drug TariffMisoprostol 200microgram tablets£10.0360 tablet1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

  • 22.3. Uterotonics · core
    Unspecified obstetric condition; Postpartum haemorrhage
    Local > Vaginal > tablet: 25 µg | Oral > Solid: 200 µg
  • 22.4. Medicines for medical abortion · complementary
    Spontaneous abortion, incomplete, without complication
    Oral > Solid > tablet: 200 µg

Safety signals and safety-related labeling changes

All safety entries for misoprostol →

Combinations containing Misoprostol

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.